Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Ends 2017 As It Started: Earnings Results Delayed

Executive Summary

The OTC drug, nutritional products and Rx generics manufacturer reported interim and unaudited results for 2017 and said it will release its entire earnings statement on a date yet to be determined because "it needs additional time to complete its final income tax review procedures related to reconciliations of specific non-cash items.2018 begins with new CEO Uwe Rohrhoff at the helm.


Related Content

Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Perrigo Taps CEO With Global Operations Expertise At Pharma Packaging Firm
Private Label Nexium OTC Buoys Perrigo As Pricing Trims Rx Revenues


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts